SEATTLE--(BUSINESS WIRE)--Athira Pharma, Inc., a clinical-stage company dedicated to developing innovative first-in-class regenerative therapies with a lead drug candidate entering Phase 2/3 clinical trials this year for Alzheimer’s disease, today announced that Dr. Leen Kawas, President and Chief Executive Officer, will present at the Jefferies Virtual Global Healthcare Conference on Thursday, June 4^th, 2020, at 2:00 p.m. ET.

Dr. Kawas will present on the current state of the company and the advancement of lead therapeutic candidate, NDX-1017, for Alzheimer’s disease as well as pipeline development for other disease indications. She will be joined by Dr. Mark J. Litton, Chief Operating Officer, and Dr. Hans J. Moebius, Chief Medical Officer.

About Athira Pharma, Inc.

Athira, headquartered in Seattle, is a drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is currently advancing its lead therapeutic candidate, NDX-1017, a novel small molecule therapeutic, in later-stage clinical trials for Alzheimer’s. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Media:
Julie Rathbun
julie.rathbun@athira.com
206-769-9219

Investor:
Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com
212-362-1200